论文部分内容阅读
硝苯吡啶(nifedipine)属于钙拮抗剂。无论是急性和慢性给药,硝苯吡啶的抗高血压临床疗效均已得到证实,但是某些有关该药的临床药理学问题仍需给予说明。本文研究硝苯吡啶中程治疗控制高血压的能力,以便提供每日最佳给药次数和维持降压作用的剂量。按照WHO有关原发性高血压分类规定选择30例患有二级和三级原发性高血压的住院病人进行研究,其中二级22人,三级8人。治疗前四周中止任何抗高血压药物,实验过程中给予正常钠饮食(每日
Nifedipine belongs to the group of calcium antagonists. The clinical efficacy of nifedipine against hypertension, both acute and chronic, has been confirmed, but some of the clinical pharmacological issues concerning this drug need to be addressed. This article investigates the ability of nifedipine to treat hypertension in order to provide the optimal number of daily doses and the amount of antihypertensive effect. Thirty patients with secondary and tertiary essential hypertension were enrolled in the study according to the WHO classification of primary hypertension, of which 22 were in secondary level and 8 in tertiary level. Four weeks prior to treatment discontinuation of any antihypertensive drugs, normal sodium diet during the experiment (daily